Seliciclib Carboxylic Acid

Seliciclib carboxylic acid is a potent inhibitor of Cyclin-Dependent Kinases (CDKs), a family of enzymes involved in cell division and proliferation. It is an important research tool in the study of cancer and other diseases that involve abnormal cell growth. Seliciclib carboxylic acid is a derivative of the original Seliciclib compound, which was discovered in the early 2000s as a potential cancer treatment. While the parent compound showed promising results in clinical trials, its development was hindered by side effects and limited efficacy. Seliciclib carboxylic acid was developed as a more potent and selective CDK inhibitor, with fewer off-target effects. In addition to its research applications, Seliciclib carboxylic acid has potential as a therapeutic agent in the treatment of cancer and other diseases. It has been shown to induce cell cycle arrest and apoptosis in cancer cells, and has demonstrated activity against a range of cancer types. However, further research is needed to determine its safety and efficacy in humans. Chemically, Seliciclib carboxylic acid is a small molecule with a molecular weight of 277.32 g/mol. Its structure includes a pyrazolylpyrimidine core and a carboxylic acid group, which is important for its activity as a CDK inhibitor. It is soluble in organic solvents such as DMSO and ethanol, but is poorly soluble in water. Its chemical properties make it well-suited for use in in vitro and in vivo studies of CDK inhibition and cancer therapy.